Genpharmasec
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Rajesh Mirchumal Sadhwani, a promoter of Genpharmasec, bought 65 lakh shares in the open market on 31 August and 1 September, taking his holding to 15.26%. With Sneha Sadhwani, his person acting in concert, the promoter group’s stake rose from 30.88% to 32.06%. A 50 lakh-share open-market purchase by Rajesh Sadhwani on 28 August had taken the group stake from 29.98% to 30.88%. Genpharmasec distributed diagnostic equipment and pharmaceutical products and reported revenue of about ₹25.5 crore in FY23.
Powered by Tijori
Rajesh Mirchumal Sadhwani, a promoter of Genpharmasec, bought 65 lakh shares in the open market on 31 August and 1 September, taking his holding to 15.26%. With Sneha Sadhwani, his person acting in concert, the promoter group’s stake rose from 30.88% to 32.06%. A 50 lakh-share open-market purchase by Rajesh Sadhwani on 28 August had taken the group stake from 29.98% to 30.88%. Genpharmasec distributed diagnostic equipment and pharmaceutical products and reported revenue of about ₹25.5 crore in FY23.
Powered by Tijori
Genpharmasec promoter Rajesh Mirchumal Sadhwani bought 50 lakh shares from the open market on 28 August 2026, raising his holding to 14.09% from 13.18%. Combined promoter holdings with PAC Sneha Sadhwani rose to 17.10 crore shares, or 30.88%, from 16.60 crore shares, or 29.98%. Sneha Sadhwani's holding remained unchanged at 9.30 crore shares, or 16.80%. Genpharmasec distributed diagnostic equipment and pharmaceutical products, and reported revenue of ₹25.5 crore in FY23.
Powered by Tijori
Genpharmasec promoter Rajesh Mirchumal Sadhwani bought 50 lakh shares from the open market on 28 August 2026, raising his holding to 14.09% from 13.18%. Combined promoter holdings with PAC Sneha Sadhwani rose to 17.10 crore shares, or 30.88%, from 16.60 crore shares, or 29.98%. Sneha Sadhwani's holding remained unchanged at 9.30 crore shares, or 16.80%. Genpharmasec distributed diagnostic equipment and pharmaceutical products, and reported revenue of ₹25.5 crore in FY23.
Powered by Tijori
Genpharmasec entered into a non-exclusive super stockist agreement with Amneal Healthcare Private Limited to distribute products manufactured by Amneal and its third-party contract manufacturers and licensors to wholesale and retail pharmacists. Amneal undertook to provide Genpharmasec with a minimum annual sales commitment of approximately ₹75 crore for each calendar year during the agreement’s term.
Powered by Tijori
Genpharmasec entered into a non-exclusive super stockist agreement with Amneal Healthcare Private Limited to distribute products manufactured by Amneal and its third-party contract manufacturers and licensors to wholesale and retail pharmacists. Amneal undertook to provide Genpharmasec with a minimum annual sales commitment of approximately ₹75 crore for each calendar year during the agreement’s term.
Powered by Tijori
July 25 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC LTD - BUYS 70% STAKE IN DERREN HEALTHCARE
Source text: ID:nBSE9VbjYB
Further company coverage: GENP.BO
(([email protected];))
July 25 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC LTD - BUYS 70% STAKE IN DERREN HEALTHCARE
Source text: ID:nBSE9VbjYB
Further company coverage: GENP.BO
(([email protected];))
Dec 10 (Reuters) - Genpharmasec Ltd GENP.BO:
ENTERS INTO AGREEMENT WITH AMNEAL HEALTHCARE
APPOINTMENT OF CO AS NONEXCLUSIVE SUPPER STOCKIST
AHPL TO PROVIDE CO WITH MINIMUM ANNUAL SALES COMMITMENT OF ABOUT 600 MILLION RUPEES
Source text: ID:nBSE1W1cxf
Further company coverage: GENP.BO
(([email protected];;))
Dec 10 (Reuters) - Genpharmasec Ltd GENP.BO:
ENTERS INTO AGREEMENT WITH AMNEAL HEALTHCARE
APPOINTMENT OF CO AS NONEXCLUSIVE SUPPER STOCKIST
AHPL TO PROVIDE CO WITH MINIMUM ANNUAL SALES COMMITMENT OF ABOUT 600 MILLION RUPEES
Source text: ID:nBSE1W1cxf
Further company coverage: GENP.BO
(([email protected];;))
Sept 20 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC EXECUTED DEFINITIVE AGREEMENT WITH DERREN HEALTHCARE AND ITS SHAREHOLDERS TO ACQUIRE 70% STAKE
OVERALL PURCHASE CONSIDERATION FOR ACQUISITION OF 70% OF DHPL IS 330 MILLION RUPEES
Source text for Eikon: ID:nBSE6jZDYH
Further company coverage: GENP.BO
(([email protected];;))
Sept 20 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC EXECUTED DEFINITIVE AGREEMENT WITH DERREN HEALTHCARE AND ITS SHAREHOLDERS TO ACQUIRE 70% STAKE
OVERALL PURCHASE CONSIDERATION FOR ACQUISITION OF 70% OF DHPL IS 330 MILLION RUPEES
Source text for Eikon: ID:nBSE6jZDYH
Further company coverage: GENP.BO
(([email protected];;))
June 5 (Reuters) - Genpharmasec Ltd GENP.BO:
APPROVED ISSUANCE OF SHARES OF AN ISSUE SIZE UPTO 490 MILLION RUPEES
APPROVED ISSUANCE OF EQUITY SHARES ON RIGHTS BASIS
Source text for Eikon: ID:nBSEc5xnSP
Further company coverage: GENP.BO
(([email protected];))
June 5 (Reuters) - Genpharmasec Ltd GENP.BO:
APPROVED ISSUANCE OF SHARES OF AN ISSUE SIZE UPTO 490 MILLION RUPEES
APPROVED ISSUANCE OF EQUITY SHARES ON RIGHTS BASIS
Source text for Eikon: ID:nBSEc5xnSP
Further company coverage: GENP.BO
(([email protected];))
May 30 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC LTD - TO CONSIDER PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE4csx5M
Further company coverage: GENP.BO
(([email protected];))
May 30 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC LTD - TO CONSIDER PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE4csx5M
Further company coverage: GENP.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Genpharmasec do?
Adi Rasayan Ltd is a company that specializes in the manufacturing and trading of organic and inorganic chemicals, dyes, and pigments.
Who are the competitors of Genpharmasec?
Genpharmasec major competitors are Bhatia Colour Chem, Seya Industries, Ishan Dyes and Chem., Chemcrux Enterprises, Metroglobal, Shankar Lal Rampal, Poddar Pigments. Market Cap of Genpharmasec is ₹65 Crs. While the median market cap of its peers are ₹122 Crs.
Is Genpharmasec financially stable compared to its competitors?
Genpharmasec seems to be less financially stable compared to its competitors. Altman Z score of Genpharmasec is 2.13 and is ranked 6 out of its 8 competitors.
Does Genpharmasec pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Genpharmasec latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Genpharmasec allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Genpharmasec balance sheet?
Balance sheet of Genpharmasec is moderately strong.
Is the profitablity of Genpharmasec improving?
The profit is oscillating. The profit of Genpharmasec is -₹0.83 Crs for TTM, ₹1.25 Crs for Mar 2025 and -₹0.13 Crs for Mar 2024.
Is the debt of Genpharmasec increasing or decreasing?
Yes, The net debt of Genpharmasec is increasing. Latest net debt of Genpharmasec is ₹22.9 Crs as of Mar-26. This is greater than Mar-25 when it was -₹7.4 Crs.
Is Genpharmasec stock expensive?
Genpharmasec is not expensive. Latest PE of Genpharmasec is 11.88, while 3 year average PE is 128. Also latest EV/EBITDA of Genpharmasec is 70.94 while 3yr average is 367.
Has the share price of Genpharmasec grown faster than its competition?
Genpharmasec has given lower returns compared to its competitors. Genpharmasec has grown at ~-21.24% over the last 4yrs while peers have grown at a median rate of -15.08%
Is the promoter bullish about Genpharmasec?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Genpharmasec is 29.98% and last quarter promoter holding is 29.98%.
Are mutual funds buying/selling Genpharmasec?
There is Insufficient data to gauge this.